Skip to main content
Taking a closer look: B-Cell depletion beyond the blood

At #ACR25, we have seen an exciting wave of cellular and immun

Dr. John Cush RheumNow

10 months 2 weeks ago
Taking a closer look: B-Cell depletion beyond the blood At #ACR25, we have seen an exciting wave of cellular and immune therapies reshaping the landscape of autoimmune disease treatment. Following the landmark case series by the Erlangen group, multiple cellular therapies have https://t.co/GIrPwlGKE2
Having #RA does not increase mortality in CA pts Rx w/ immune checkpoint inhibitors (ICI). 301 Veterans w/ RA & 2114

Dr. John Cush RheumNow

10 months 2 weeks ago
Having #RA does not increase mortality in CA pts Rx w/ immune checkpoint inhibitors (ICI). 301 Veterans w/ RA & 2114 nonRA controls were compared: all-cause mortality was similar (HR 1.09; 0.94, 1.25). Most deaths from cancer (90% & 91%), but rarely from infection (<1%) https://t.co/gsXie6HpTu
SLE Prospect. Observational Study of 826 SLE pts over 3 yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high.

Dr. John Cush RheumNow

10 months 2 weeks ago
SLE Prospect. Observational Study of 826 SLE pts over 3 yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high. IFNGS-high pts were younger. on GC w/ Hi SLEDAI-2K. SLEDAI-2K decreased over time, regardless of IFNGS. By 36mos, 45% had ≥1 flare; higher in IFNGS. https://t.co/c3zHT2GfR5
IL-1 Inhibition in CPPD

Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) ar

Dr. John Cush RheumNow

10 months 2 weeks ago
IL-1 Inhibition in CPPD Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares. https://t.co/7RkE2i6sYY
DAHLIAS study - Nipocalimab in Sjögren's Disease

Nipocalimab, a neonatal Fc receptor blocker that reduces circulating

Dr. John Cush RheumNow

10 months 2 weeks ago
DAHLIAS study - Nipocalimab in Sjögren's Disease Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease. https://t.co/tpoh8YF0F1 https://t.co/jFB1RKOqDV
In a new study involving 402 U.S.-based primary care physicians, researchers from Northwestern University and the University of Sydney identified a “sweet spot” in clinical decision-making. By presenting just the right number of treatment alternatives in the electronic health record (EHR) system, physicians were more likely to choose a high-quality alternative rather than defaulting to the status quo.
A cohort study shows that hospitalized patients with dermatomyositis have higher in-hospital mortality in the presence of active rash, interstitial lung disease, and elevated neutrophil to lymphocyte ratio at admission.Dermatomyositis (DM) has significiant morbidity and mortality risks; but is this altered with DM patients who are hospitalized? 
Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic a

Dr. John Cush RheumNow

10 months 2 weeks ago
Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic autoimmune response in SLE https://t.co/vjpvILrJOt https://t.co/HepyZrYW5L
Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis? Mesothelin is elevated in RA & a

Dr. John Cush RheumNow

10 months 2 weeks ago
Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis? Mesothelin is elevated in RA & animal models & promothes osteoclast differentiation & bony destruction. Blocking mesothelin has the potential to reduce bone destruction. https://t.co/WRXG91AqmJ https://t.co/hMgddPXhxG
Day 2 Recap: #ACR25 Highlights

Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as the

Dr. John Cush RheumNow

10 months 2 weeks ago
Day 2 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap. https://t.co/aBxLuDhIMC https://t.co/q75eHf45Gt
CAR-T Therapy: Where is it Heading?

Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25.

Dr. John Cush RheumNow

10 months 2 weeks ago
CAR-T Therapy: Where is it Heading? Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25. https://t.co/bC8p1LnZMW https://t.co/KKn3jjsBW0
Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI

AI continues to move from research labs into rheu

Dr. John Cush RheumNow

10 months 2 weeks ago
Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. AS, in particular, poses a diagnostic challenge—its early imaging https://t.co/TH2YIiPPEq
Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fo

Dr. John Cush RheumNow

10 months 2 weeks ago
Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1).
Sjögren's disease RCTs: Has the Long Drought Ended?

At #ACR25, two late breaking abstracts have triggered hope for pa

Dr. John Cush RheumNow

10 months 2 weeks ago
Sjögren's disease RCTs: Has the Long Drought Ended? At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease. https://t.co/nNNx5sXzCz https://t.co/r9VBgyYgOC
PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use

Drs. Jiha Lee and Shivani Garg discuss abstract 1052

Dr. John Cush RheumNow

10 months 2 weeks ago
PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use Drs. Jiha Lee and Shivani Garg discuss abstract 1052 (“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic https://t.co/ZBH61Uzzc8
×